ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Chinese pursuit of Avigan patent faces pushback in Japan

Fujifilm intellectual property cited as reason to 'reject' Beijing lab's application

The patent filing by China's Academy of Military Medical Sciences covers favipiravir, the generic name for Avigan, as a treatment for COVID-19.

TOKYO -- A Chinese lab attempting to patent the use of anti-flu drug Avigan for the treatment of COVID-19 is facing pushback in Japan, where the medicine was originally developed.

The Beijing-based Academy of Military Medical Sciences obtained a patent for the use of favipiravir, the chemical compound behind Avigan, in China earlier this year, and has applied for similar intellectual property rights in Japan, the U.S. and Europe.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more